Circulating MicroRNAs as Noninvasive Diagnostic Biomarkers of Liver Disease in Children With Cystic Fibrosis

被引:35
作者
Cook, Naomi L. [1 ]
Pereira, Tamara N. [1 ]
Lewindon, Peter J. [2 ]
Shepherd, Ross W. [3 ]
Ramm, Grant A. [1 ]
机构
[1] QIMR Berghofer Med Res Inst, Hepat Fibrosis Grp, Brisbane, Qld 4029, Australia
[2] Royal Childrens Hosp, YDepartment Gastroenterol, Brisbane, Qld, Australia
[3] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
cystic fibrosis liver disease; hepatic fibrosis; pediatrics; reference genes; RT-qPCR; serum miRNA; SERUM; FIBROGENESIS; EXPRESSION; MANAGEMENT; HEPATITIS; MARKERS; CANCER; CELLS; POWER; NEED;
D O I
10.1097/MPG.0000000000000600
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: Cystic fibrosis liver disease (CFLD), resulting from progressive hepatobiliary fibrosis, causes significant morbidity and mortality in up to 20% of children with cystic fibrosis (CF). Both pathogenesis and early detection of CFLD are elusive. Current diagnostic procedures to detect early CFLD and stage fibrosis severity are inadequate. Recent studies highlight a role for microRNAs (miRNAs) in the pathogenesis of many diseases and have suggested that serum miRNAs could be used as diagnostic biomarkers. Methods: We profiled circulating serum miRNA levels in patients with CFLD (n = 52), patients with CF without liver disease (CFnoLD, n = 30), and non-CF pediatric controls (n = 20). Extracted RNA was subjected to polymerase chain reaction (PCR) array of 84 miRNAs detectable in human serum. Seven candidate miRNAs identified were validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR), normalizing data to geNorm-determined stable reference genes, miR-19b and miR-93. Results: miR-122 was significantly elevated in patients with CFLD versus patients with CFnoLD and controls (P < 0.0001). miR-25 (P = 0.0011) and miR-21 (P = 0.0133) were elevated in patients with CFnoLD versus patients with CFLD and controls. CFLD was discriminated by both miR-122 (area under the curve [AUC] 0.71, P = 0.002) and miR-25 (AUC 0.65, P = 0.026). Logistic regression combining 3 miRNAs (-122, -25, -21) was greatly predictive of detecting CFLD (AUC 0.78, P < 0.0001). A combination of 6 miRNAs (-122, -21, -25, -210, -148a, -19a) distinguished F0 from F3-F4 fibrosis (AUC 0.73, P = 0.04), and miR-210 combined with miR-22 distinguished F0 fibrosis from any fibrosis, that is, F1-F4 (AUC 0.72, P = 0.02). Conclusions: These data provide the first evidence of changes to circulating miRNA levels in CF, suggesting that serum-based miRNA analysis may complement and extend current CFLD screening strategies with potential to predict early hepatic fibrosis.
引用
收藏
页码:247 / 254
页数:8
相关论文
共 48 条
[1]   Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases [J].
Bala, Shashi ;
Petrasek, Jan ;
Mundkur, Shiv ;
Catalano, Donna ;
Levin, Ivan ;
Ward, Jeanine ;
Alao, Hawau ;
Kodys, Karen ;
Szabo, Gyongyi .
HEPATOLOGY, 2012, 56 (05) :1946-1957
[2]   MicroRNA profiling of cystic fibrosis intestinal disease in mice [J].
Bazett, Mark ;
Paun, Alexandra ;
Haston, Christina K. .
MOLECULAR GENETICS AND METABOLISM, 2011, 103 (01) :38-43
[3]   Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma [J].
Bihrer, Verena ;
Waidmann, Oliver ;
Friedrich-Rust, Mireen ;
Forestier, Nicole ;
Susser, Simone ;
Haupenthal, Joerg ;
Welker, Martin ;
Shi, Ying ;
Peveling-Oberhag, Jan ;
Polta, Andreas ;
von Wagner, Michael ;
Radeke, Heinfried H. ;
Sarrazin, Christoph ;
Trojan, Joerg ;
Zeuzem, Stefan ;
Kronenberger, Bernd ;
Piiper, Albrecht .
PLOS ONE, 2011, 6 (10)
[4]   MicroRNAs, transforming growth factor beta-1, and tissue fibrosis [J].
Bowen, Timothy ;
Jenkins, Robert H. ;
Fraser, Donald J. .
JOURNAL OF PATHOLOGY, 2013, 229 (02) :274-285
[5]   The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments [J].
Bustin, Stephen A. ;
Benes, Vladimir ;
Garson, Jeremy A. ;
Hellemans, Jan ;
Huggett, Jim ;
Kubista, Mikael ;
Mueller, Reinhold ;
Nolan, Tania ;
Pfaffl, Michael W. ;
Shipley, Gregory L. ;
Vandesompele, Jo ;
Wittwer, Carl T. .
CLINICAL CHEMISTRY, 2009, 55 (04) :611-622
[6]   Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease [J].
Cermelli, Silvia ;
Ruggieri, Anna ;
Marrero, Jorge A. ;
Ioannou, George N. ;
Beretta, Laura .
PLOS ONE, 2011, 6 (08)
[7]   Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases [J].
Chen, Xi ;
Ba, Yi ;
Ma, Lijia ;
Cai, Xing ;
Yin, Yuan ;
Wang, Kehui ;
Guo, Jigang ;
Zhang, Yujing ;
Chen, Jiangning ;
Guo, Xing ;
Li, Qibin ;
Li, Xiaoying ;
Wang, Wenjing ;
Zhang, Yan ;
Wang, Jin ;
Jiang, Xueyuan ;
Xiang, Yang ;
Xu, Chen ;
Zheng, Pingping ;
Zhang, Juanbin ;
Li, Ruiqiang ;
Zhang, Hongjie ;
Shang, Xiaobin ;
Gong, Ting ;
Ning, Guang ;
Wang, Jun ;
Zen, Ke ;
Zhang, Junfeng ;
Zhang, Chen-Yu .
CELL RESEARCH, 2008, 18 (10) :997-1006
[8]  
D'haene Barbara, 2012, Methods Mol Biol, V822, P261, DOI 10.1007/978-1-61779-427-8_18
[9]   Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease [J].
Debray, Dominique ;
Kelly, Deirdre ;
Houwen, Roderick ;
Strandvik, Birgitta ;
Colombo, Carla .
JOURNAL OF CYSTIC FIBROSIS, 2011, 10 :S29-S36
[10]   Cirrhosis and other liver disease in cystic fibrosis [J].
Flass, Thomas ;
Narkewicz, Michael R. .
JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (02) :116-124